Moving its lab and U.S. headquarters to Research Triangle Park supports the strategy Immunovia announced in July 2023 to streamline operations and reduce costs.

The move to Research Triangle Park follows Immunovia’s model development study and completion of the discovery phase for its next-generation test in November 2023. Following these developments, the company will focus on confirming the analytical validity of its new test and conducting a large clinical validation study. This work will be conducted at the lab in Research Triangle Park under the leadership and direction of Dr. Lisa Ford.

Read more: Immunovia announces partly inconclusive study results

The new space in Research Triangle Park (RTP) will be significantly smaller and less expensive than the company’s existing lab in Marlborough, Massachusetts, the company states. The lower cost of labor in Research Triangle Park should enable the company to staff the new lab at a lower cost.

“Research Triangle Park offers access to top talent at a reasonable cost. Moving to a smaller lab in RTP is a key aspect of our ongoing efforts to be a leaner, more efficient company,” says Jeff Borcherding, CEO and President of Immunovia.

Photo of Jeff Borcherding